Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes

K Decochez, I Truyen, B van der Auwera, I Weets, E Vandemeulebroucke, I H de Leeuw, B Keymeulen, C Mathieu, R Rottiers, D G Pipeleers, F K Gorus, Belgian Diabetes Registry, K Decochez, I Truyen, B van der Auwera, I Weets, E Vandemeulebroucke, I H de Leeuw, B Keymeulen, C Mathieu, R Rottiers, D G Pipeleers, F K Gorus, Belgian Diabetes Registry

Abstract

Aims/hypothesis: Prevention trials in first-degree relatives of type 1 diabetic patients are hampered by large interindividual differences in progression rate to diabetes. We investigated whether specific combinations of immune and genetic markers can identify subgroups with more homogeneous progression to clinical onset.

Methods: Antibodies against islet cell cytoplasm (ICA), insulin (IAA), glutamate decarboxylase (GADA) and IA-2 protein (IA-2A) were measured in 790 non-diabetic control subjects and 4,589 first-degree relatives under age 40.

Results: On first sampling, 11.1% of the siblings presented at least one antibody type (p<0.001 vs other relatives). During follow-up (median 52 months) 43 subjects developed type 1 diabetes (31 siblings, ten offspring of a diabetic father, two offspring of a diabetic mother). Using Kaplan-Meier survival analysis and Cox regression, IA-2A conferred the highest 5-year diabetes risk (>50%) irrespective of the number of antibodies present. In initially IA-2A-positive relatives (n=58) progression to hyperglycaemia depended more on HLA DQ status than on type of kinship (84% progression in the presence of DQ2/DQ8 vs 32% in its absence; p<0.003). In IA-2A-negative relatives (n=4,531) 5-year progression to diabetes increased with the number of other antibodies (ICA, GADA and/or IAA) (p<0.001) but overall did not exceed 10% even for two or more antibodies. Among relatives initially positive for one or more antibody type other than IA-2A (n=315), there was significantly more progression to diabetes (overall still <10%) in carriers of DQ2 (p<0.001 vs no DQ2), regardless of DQ8 status.

Conclusions/interpretation: These observations suggest that the HLA-DQ-inferred risk of diabetes can proceed through two distinct pathways distinguished by IA-2A status. Combined positivity for DQ2/DQ8 and IA-2A defines a more homogeneous high-risk population for prevention trials than those used so far.

References

    1. J Clin Endocrinol Metab. 1994 May;78(5):1172-8
    1. J Clin Endocrinol Metab. 1994 Dec;79(6):1570-5
    1. N Engl J Med. 2002 May 30;346(22):1685-91
    1. Diabetologia. 1996 Oct;39(10):1223-6
    1. Autoimmunity. 1999;29(1):57-63
    1. Nat Genet. 1998 Jul;19(3):301-2
    1. J Clin Invest. 1992 Dec;90(6):2242-50
    1. Diabetologia. 1997 Jan;40(1):95-9
    1. Diabetes. 1979 Dec;28(12):1039-57
    1. Diabetes. 1996 Jul;45(7):926-33
    1. Diabetes. 1993 Feb;42(2):213-20
    1. Endocr Rev. 1997 Apr;18(2):241-58
    1. Diabetes. 2004 Feb;53(2):384-92
    1. Diabetes. 2003 May;52(5):1128-36
    1. Diabetes. 1999 Mar;48(3):460-8
    1. J Autoimmun. 1999 Jun;12(4):279-87
    1. Diabetes Care. 1997 Oct;20(10):1547-52
    1. Arch Dis Child. 1995 Jul;73(1):25-9
    1. J Clin Endocrinol Metab. 1995 Sep;80(9):2567-73
    1. Diabetologia. 2002 Dec;45(12):1658-66
    1. N Engl J Med. 1985 Aug 22;313(8):461-4
    1. Diabetes. 1998 Dec;47(12):1857-66
    1. Lancet. 2004 Mar 20;363(9413):925-31
    1. J Clin Endocrinol Metab. 2000 Jul;85(7):2421-8
    1. J Clin Endocrinol Metab. 1996 Dec;81(12):4264-7
    1. Diabetes Care. 2000 Jun;23(6):838-44
    1. Diabetes Care. 1997 Jun;20(6):1027-33
    1. Diabetes Care. 1996 Mar;19(3):278-86
    1. Diabetes. 2002 May;51(5):1346-55
    1. Diabetes. 2002 Mar;51(3):646-51
    1. Cancer Chemother Rep. 1966 Mar;50(3):163-70
    1. J Clin Invest. 1998 Jan 15;101(2):327-36
    1. BMJ. 1995 Jan 21;310(6973):170
    1. Diabetologia. 2001 Jan;44(1):40-7
    1. Diabetologia. 1999 Jan;42(1):3-14
    1. Diabetologia. 1986 Apr;29(4):207-10
    1. Diabetologia. 2001 Jan;44(1):3-15
    1. N Engl J Med. 1984 Jul 19;311(3):149-52
    1. Best Pract Res Clin Endocrinol Metab. 2001 Sep;15(3):371-89
    1. Diabetes. 1994 Nov;43(11):1304-10

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa